GSK plc (GSK) ORD GBP0.3125

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
EMA accepts marketing authorisation application for GSK's linerixibat
23 June 2025 11:07
(Sharecast News) - GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in...
-
GSK hoping to expand Arexvy usage in Japan
20 June 2025 07:19
(Sharecast News) - Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult population.
-
GSK's RSV vaccine accepted for regulatory review by EMA
13 June 2025 07:01
(Sharecast News) - Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older.
-
Berenberg downgrades GSK to 'hold' ahead of product rollouts
3 June 2025 10:18
(Sharecast News) - Analysts at Berenberg downgraded drugmaker GSK from 'buy' to 'hold' on Tuesday as it awaited upcoming product launches.
-
GSK's linerixibat to be reviewed by US FDA
2 June 2025 07:40
(Sharecast News) - Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US Food and Drug Administration for use in cholestatic pruritus...
-
GSK, Spero UTI drug trial ends early after meeting target
28 May 2025 13:19
(Sharecast News) - UK pharma giant GSK and its partner Spero Therapeutics on Wednesday said it had ended a late-stage trial of an experimental drug for complicated urinary tract infections early after it met...
-
GSK's COPD treatment approved by FDA
23 May 2025 07:20
(Sharecast News) - Pharma group GSK has announced that US regulators have approved for use its Nucala treatment for adults with chronic obstructive pulmonary disease (COPD) following positive results from...
-
GSK's blood cancer treatment approved in Japan
19 May 2025 07:41
(Sharecast News) - GSK's Blenrep treatment has been approved by Japanese regulators when in combination for relapsed or refractory multiple myeloma, marking the second major approval of its kind for the...
-
London close: Stocks finish choppy week in the black
16 May 2025 16:32
(Sharecast News) - London equities ended the week higher on Friday, supported by gains in pharmaceutical and energy stocks.
-
GSK buys Boston's developmental liver disease drug for up to $2bn
14 May 2025 07:18
(Sharecast News) - GSK announced on Wednesday that it has entered into an agreement with Boston Pharmaceuticals to acquire its lead asset Efimosfermin for up to $2bn, buying a specialty medicine to treat and...
-
Pharma stocks slide as Trump threatens price cuts in US
12 May 2025 10:13
(Sharecast News) - Shares in pharmaceutical companies fell on Monday after US President Donald Trump threatened to sign an executive order to slash the price of prescription drugs for Americans.
-
Sunday newspaper round-up: US-China, Aerospace, Pharma
11 May 2025 14:38
(Sharecast News) - The US president said talks with China that were taking place in Geneva had achieved a "total reset" in the two countries' trade relations. Without elaborating, Donald Trump...
Company announcements Announcements
-
Transaction in Own Shares
26 June 2025 07:00
GSK
-
Transaction in Own Shares
25 June 2025 07:00
GSK
-
Director/PDMR Shareholding
24 June 2025 15:30
GSK
-
Director Declaration
24 June 2025 15:00
GSK
-
Transaction in Own Shares
24 June 2025 07:00
GSK
-
Replacement - Director/PDMR Shareholding
23 June 2025 17:50
GSK
-
Director/PDMR Shareholding
23 June 2025 15:30
GSK
-
Replacement RNS: Linerixibat file accepted by EMA
23 June 2025 08:30
GSK
-
GSK Submits Arexvy for adults 18+ with EMA
23 June 2025 08:18
GSK
-
Transaction in Own Shares
23 June 2025 07:00
GSK
-
Arexvy filed in Japan for 18-49 at increased risk
20 June 2025 07:00
GSK
-
Transaction in Own Shares
20 June 2025 07:00
GSK
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.